Award details

Large scale lentiviral vector production

Reference	BB/M028992/1
Principal Investigator / Supervisor	Dr Martin Pule
Co-Investigators / Co-Supervisors	Professor Waseem Qasim, Dr Yasuhiro Takeuchi, Professor Adrian Thrasher, Dr Pamela Tranter
Institution	University College London
Department	Haematology
Funding type	Research
Value (£)	1,436,653
Status	Completed
Type	Research Grant
Start date	01/05/2015
End date	30/09/2018
Duration	41 months

Abstract

* Lentiviral vectors (LV) are used to genetically modify target cells. The main commercial application of LVs is in vitro production of cellular therapeutics, although they can be used as therapeutic agents in their own right and for generation of protein producer cells. While small-scale production is well established, a process for very large-scale production has not been developed. Recently, commercial demand for LV has increased greatly. Large-scale production is a major unmet need and its lack a bottleneck esp. in the marketing of cellular therapies. The challenge of large-scale LV production is multifaceted, requiring a deep understanding of lentiviral biology, as well as skilful genetic and cellular engineering, appreciation of regulatory / GMP considerations, industrial/pharmaceutical scale production issues as well as an understanding of the down-stream clinical applications.

Summary

Lentiviral vectors (LV) are remarkable in their ability to insert their genetic payload into a target cell's genome. This affects a permanent genetic change in the target which is propagated through to its progeny. While there are several means of genetic modification, few are capable of permanent modification of target cells. Amongst all vectors for gene delivery, LV are unique in unparalleled efficiency, safety, lack of toxicity and ability to modify non-dividing target cells. They have therefore come to be recognised as a key reagent required for the efficient development of the burgeoning cell therapy, as well as gene therapy industries. However, although LV represent a well understood and robust technology, there is no manufacturing methodology for very large-scale LV production. This is now an acknowledged bottle-neck both for clinical trials and for commercial exploitation of many cell and gene therapy products in current development. We propose to address this unmet need

Impact Summary

As described in proposal submitted to IUK

Committee	Research Committee A (Animal disease, health and welfare)
Research Topics	Industrial Biotechnology, Microbiology, Pharmaceuticals, Technology and Methods Development
Research Priority	X – Research Priority information not available
Research Initiative	Industrial Biotechnology Catalyst (IBCAT) [2014-2015]
Funding Scheme	X – not Funded via a specific Funding Scheme

Associated awards:

BB/N003853/1 Large scale lentiviral vector production

I accept the terms and conditions of use (opens in new window)

export PDF file

back to list new search